Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. May 4, 2018. Sean Boyd.

Executive Summary

As the global Medical Device Single Audit Program gets off the ground, US FDA says it sees additional ways MDSAP audits could support its regulatory mission. See what FDA official Sean Boyd said about it here.

"Could we apply them in situations other than for routine surveillance inspections? Could we think about accepting an MDSAP audit report for a pre-approval inspection?" – Sean Boyd, deputy director for regulatory affairs, Office of Compliance, FDA's Center for Devices and Radiological Health

Click here for a free trial to Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel